Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2005
12/29/2005WO2005072091A3 Methods for inhibiting hiv and other viral infections by modulating ceramide metabolism
12/29/2005WO2005067500A3 Enhancement of immune responses
12/29/2005WO2005065121A3 Methods and compositions for the production of monoclonal antibodies
12/29/2005WO2005062882A3 Rifamycin analogs and uses thereof
12/29/2005WO2005062828A3 New compounds useful as metal chelators
12/29/2005WO2005060981A3 Pharmaceutical compositions
12/29/2005WO2005060939A3 Controlled-release pharmaceutical formulation
12/29/2005WO2005058373A3 Methods, program products, and systems for single and multi-agent dosing
12/29/2005WO2005055939A3 Vinca derivatives
12/29/2005WO2005053661A3 Pharmaceutical combinations
12/29/2005WO2005051974A3 Novel molecules for regulating cell death
12/29/2005WO2005049088A3 Combination of a dpp iv inhibitor and an antiobesity or appetite regulating agent
12/29/2005WO2005048952A3 Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle
12/29/2005WO2005047524A3 Compositions and methods for inducing cell dedifferentiation
12/29/2005WO2005046618A3 Methods of treating eczema
12/29/2005WO2005046608B1 Novel compound, corresponding compositions, preparation and/or treatment methods
12/29/2005WO2005046595A3 Hif-1 inhibitors and methods of use thereof
12/29/2005WO2005046580A3 Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism
12/29/2005WO2005042552A3 Modulation of sglt2 expression
12/29/2005WO2005037256B1 Liquid preparation containing tobramycin
12/29/2005WO2005034881A3 Methods and compositions for treating conditions involving abnormal angiogenesis
12/29/2005WO2005034879A3 Treatment of diseases involving erbb2 kinase overexpression
12/29/2005WO2005018563A3 Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
12/29/2005WO2005018562A3 Blockade of mtor to prevent a hormonal adaptive response
12/29/2005WO2005016273A3 Infection prophylaxis using immune response modifier compounds
12/29/2005WO2005016243A3 Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders
12/29/2005WO2005013918A3 Compositions, methods and kits relating to poxvirus subunit vaccines
12/29/2005WO2005012294A8 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
12/29/2005WO2005011618A3 Methods for the treatment of male and female sexual dysfunction
12/29/2005WO2005007625A3 Heterocyclic amides with anti-tuberculosis activity
12/29/2005WO2005000203A3 Methods for treating cognitive impairment and improving cognition
12/29/2005WO2004108076A3 Anti-hiv benzamide compounds
12/29/2005WO2004106295A3 Substituted piperodines and pyrrolidines as calcium sensing receptor modulators and method
12/29/2005WO2004094599A3 Disease prevention and vaccination following thymic reactivation
12/29/2005WO2004092122A3 Preparation and purification of synthetic capsaicin
12/29/2005WO2004084832A3 Measurement of estrogen activity in plants and a composition therefrom
12/29/2005WO2004082636A3 Combination of an aldosterone receptor antagonist and a neutral endopeptidase inhibitor
12/29/2005WO2004082631A3 METHODS FOR PREPARATION AND USE OF 1α,24(S)-DIHYDROXYVITAMIN D2
12/29/2005WO2004073658A3 Isoflavone derivatives
12/29/2005WO2004069166A3 Inhibition of hiv-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein
12/29/2005WO2004062582A3 Combination therapy for anticoagulation
12/29/2005WO2004034965A3 Method for treating cancer
12/29/2005WO2004004661A3 Boroproline compound combination therapy
12/29/2005WO2002099040A3 Igs as modifiers of the p53 pathway and methods of use
12/29/2005US20050289660 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
12/29/2005US20050289658 System for regulating in vivo the expression of a transgene by conditional inhibition
12/29/2005US20050288651 Apparatus with weeping tip and method of use
12/29/2005US20050288515 Chemical compounds
12/29/2005US20050288514 Desorption from synthetic resin with a weakly polar or apolar solvent; and separation of epothilones A and B by reversed-phase chromatography after being taken up in a suitable solvent and elution with a mixture of nitrile and water; desolventizing; crylstallization; industrial scale; efficiency
12/29/2005US20050288513 Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
12/29/2005US20050288502 Substituted heterocyclic compounds and methods of use
12/29/2005US20050288501 Reducing a 2-(protected amino)-3-(piperazin-1-yl, N-morpholinyl, or N-thiomorpholinyl) propanoate, deprotecting the amine, and reacting with t-butylisothiocyanate
12/29/2005US20050288487 Human mast cell-expressed membrane proteins
12/29/2005US20050288379 Benzoquinone compounds as anti-cancer agents
12/29/2005US20050288378 Cancer chemotherapy
12/29/2005US20050288377 Use of calcimimetic as an adynamic bone disease related treatment
12/29/2005US20050288376 Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides
12/29/2005US20050288375 Method and composition for treating neurodegenerative disorders
12/29/2005US20050288374 Chemical stabilization of solubilized retinoids and aqueous compositions comprised thereof
12/29/2005US20050288373 Methods of treating various conditions by administration of sustained release L-arginine
12/29/2005US20050288372 Also including 0.5-5 % polyvinylpyrrolidone and 5-40 % hydroxypropyl methylcellulose; administering an endothelial nitric oxide synthase agonist (an HMG-CoA reductase inhibitor) and a NO precursor (L-arginine hydrochloride) for cerebrovascular/cardiovascular disorders; anticholesterol agents
12/29/2005US20050288371 Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
12/29/2005US20050288370 Polymorphic forms are suitable for use as active substances of pharmaceutical dosage forms for reduction of serum cholesterol levels in the bloodstream
12/29/2005US20050288368 Compositions and methods for treating and preventing necrosis
12/29/2005US20050288367 Benzyloxy derivatives as MAOB inhibitors
12/29/2005US20050288366 Administering N-(4-carboxybutyl)-N-(p-carboxybenzyl)-benzyl- or phenethyl-amine derivatives: 4-({(4-Carboxybutyl)[3-(4-cyclohexylphenoxy)benzyl]amino}methyl)-benzoic acid; stimulate soluble guanylate cyclase also via a novel mechanism of action which takes place without involvement of the heme group
12/29/2005US20050288365 Platinum complexes and methods for inhibiting tumor cell proliferation
12/29/2005US20050288364 Halogenated triptolide derivatives as immunomodulators and anticancer agents
12/29/2005US20050288363 Therapeutic compositions and methods of use
12/29/2005US20050288362 tocotrienol is selected from the group consisting of alpha , beta , gamma , or delta tocotrienol, or a combination thereof
12/29/2005US20050288361 Applying to the skin a 5,7-dihydroxy-3-[(4-methoxyphenyl)methyl]-6,8-dimethyl-chroman-4-on (methylophiopogonanone B ) for reducing dyschromatosis on which tyrosinase inhibitors have insufficient effect
12/29/2005US20050288360 Nutraceutical compositions comprising epigallocatechin gallate and raspberry ketone
12/29/2005US20050288359 Agents and methods for the treatment of disorders associated with oxidative stress
12/29/2005US20050288358 In which the amino is substituted by arylmethyl- or heteroarylmethyl- group, e.g., 2-Methoxybenzyl)-(2-phenylpyrrolidin-3-yl)-amine and 5-{[2-(3-Chloro-phenyl)-pyrrolidin-3-ylamino]-methyl}-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphalen-2-one; neurokinin 1 (Substance P) inhititors
12/29/2005US20050288357 e.g. 4-(2-{2-[4-hydroxy-4-(1-propylcyclobutyl)but-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid; antiinflammatory, hypotensive, antiulcer agent
12/29/2005US20050288355 Combination therapy wherein a serotonin reuptake inhibitor is used
12/29/2005US20050288353 Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
12/29/2005US20050288352 Lactam fermentation products, e.g., pyrrolooxetanediones or pyrrolothietanediones especially containing a cyclohexane or cyclohexane ring, used as antimicrobial, anticancer or antiinflammatory agents; treating drug resistant cancer
12/29/2005US20050288351 Azaspiro compounds for the treatment of pain
12/29/2005US20050288350 Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer; 6-(bis-2,2,2-Trifluoroethyl)amino-4-trifluoromethylcoumarin
12/29/2005US20050288349 Cancer treatments and pharmaceutical compositions therefor
12/29/2005US20050288348 Compounds and methods for use thereof in the treatment of cancer
12/29/2005US20050288347 Certain triazole-based compounds, compositions, and uses thereof
12/29/2005US20050288346 Acetophenone potentiators of metabotropic glutamate receptors
12/29/2005US20050288345 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
12/29/2005US20050288344 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
12/29/2005US20050288343 Process of preparing substituted carbamates and intermediates thereof
12/29/2005US20050288341 thiazolidin-2,4-diones or -oxazolidin-2,4-diones or thiones; obesity, inflammation, autoimmune diseases (multiple sclerosis, rheumatoid arthritis); increase the leptin level; no liver toxicity; inhibits TNF- alpha , IL-1, IL-6, IL-1 beta and cyclooxygenase COX-2; no affinity for PPAR-g; non-adipogenic.
12/29/2005US20050288340 Substituted heteroaryl- and phenylsulfamoyl compounds
12/29/2005US20050288339 Medicinal compositions containing diuretic and insulin resistance-improving agent
12/29/2005US20050288338 Amido compounds and their use as pharmaceuticals
12/29/2005US20050288337 Novel compounds
12/29/2005US20050288336 Cysteine protease inhibitors
12/29/2005US20050288335 Triamide-substituted heterobicyclic compounds
12/29/2005US20050288333 Controlling angiogenesis with anabaseine analogs
12/29/2005US20050288332 Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2ylmethyl)piperidin-4-yl]-1h- pyrrole mono-hydrochloride
12/29/2005US20050288331 Compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
12/29/2005US20050288330 Process for producing a polymorphic form of (1-Benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride)
12/29/2005US20050288329 2-(4-Chlorophenyl)-N-[(1R,2R)-2-(benzyloxy)cyclohexyl]-2-methylpropanamide; modulators of 11- beta hydroxyl steroid dehydrogenase type 1 and/or mineralocorticoid receptor
12/29/2005US20050288328 a mixture of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and antiinsomnia drug, used for treating sleep and psychological disorders
1 ... 4416 4417 4418 4419 4420 4421 4422 4423 4424 4425 4426 4427 4428 4429 4430 4431 4432 4433 4434 4435 4436 ... 7860